ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Q1 2026 vs. Q4 2025
How the institutions holding ARS Pharmaceuticals, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 191 | 3 | 203 | +15 |
| Shares | 90.2M | 3.52M | 94.1M | +7.47M (+8.6%) |
| Value | $1.05B | $41.0M | $757.5M | −$251.6M (−24.9%) |
3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (40)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (25)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Casdin Capital, LLC | 1,600,000 | $18.6M |
| Southpoint Capital Advisors LP | 1,500,000 | $17.5M |
| Bank of Montreal | 643,407 | $7.50M |
| Alyeska Investment Group, L.P. | 418,883 | $4.88M |
| Lisanti Capital Growth, LLC | 396,509 | $4.62M |
| Creek Drive Management Group LLC | 295,863 | $3.45M |
| Woodline Partners LP | 150,936 | $1.76M |
| Trexquant Investment LP | 150,100 | $1.75M |
| Principal Financial Group Inc | 112,766 | $1.31M |
| Legato Capital Management LLC | 109,095 | $1.27M |
| SG Americas Securities, LLC | 76,203 | $888.0K |
| HRT Financial LP | 68,645 | $799.0K |
| Fox Run Management, L.L.C. | 38,587 | $449.5K |
| Quest Partners LLC | 32,970 | $384.1K |
| Wealthspire Advisors, LLC | 23,650 | $275.5K |
| Cetera Investment Advisers | 15,340 | $178.7K |
| Lazard Asset Management LLC | 14,347 | $167.1K |
| Cygnus Capital Advisors, LLC | 10,556 | $123.0K |
| Wealth Architects, LLC | 10,000 | $116.5K |
| Torren Management, LLC | 2,762 | $32.2K |
| Amalgamated Bank | 1,853 | $22.0K |
| Daiwa Securities Group Inc. | 367 | $4.00K |
| Quarry LP | 250 | $2.91K |
| Key Financial Inc | 200 | $2.33K |
| Tripletail Wealth Management, LLC | 100 | $1.17K |
Not filed for Q1 2026 yet (3)
Institutions that held ARS Pharmaceuticals, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 3,509,174 | $40.9M |
| Sherbrooke Park Advisers LLC | 13,139 | $153.1K |
| Comerica Bank | 217 | $2.53K |